Amneal Pharmaceuticals, Inc.
AMRX
$6.98
$0.010.14%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.79B | 2.68B | 2.60B | 2.50B | 2.39B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.79B | 2.68B | 2.60B | 2.50B | 2.39B |
| Cost of Revenue | 1.78B | 1.70B | 1.65B | 1.58B | 1.53B |
| Gross Profit | 1.02B | 979.05M | 943.11M | 913.40M | 863.87M |
| SG&A Expenses | 476.44M | 456.75M | 451.07M | 440.17M | 429.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 0.00 | 73.00K | 86.00K | -1.14M |
| Total Operating Expenses | 2.45B | 2.34B | 2.27B | 2.19B | 2.12B |
| Operating Income | 348.36M | 339.77M | 329.16M | 308.59M | 271.38M |
| Income Before Tax | -55.01M | -123.16M | -115.62M | -106.37M | -40.27M |
| Income Tax Expenses | 18.86M | 23.32M | 17.58M | 13.94M | 8.45M |
| Earnings from Continuing Operations | -73.88 | -146.48 | -133.20 | -120.31 | -48.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -43.01M | -37.98M | -41.41M | -48.39M | -35.27M |
| Net Income | -116.89M | -184.45M | -174.62M | -168.69M | -83.99M |
| EBIT | 348.36M | 339.77M | 329.16M | 308.59M | 271.38M |
| EBITDA | 584.55M | 566.76M | 554.39M | 535.36M | 500.78M |
| EPS Basic | -0.38 | -0.68 | -0.62 | -0.56 | -0.31 |
| Normalized Basic EPS | -0.07 | 0.01 | 0.02 | 0.01 | 0.04 |
| EPS Diluted | -0.38 | -0.69 | -0.63 | -0.57 | -0.32 |
| Normalized Diluted EPS | -0.07 | 0.01 | 0.02 | 0.01 | 0.04 |
| Average Basic Shares Outstanding | 1.24B | 1.17B | 1.01B | 858.95M | 703.78M |
| Average Diluted Shares Outstanding | 1.25B | 1.18B | 1.03B | 865.57M | 710.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
